UB Paderborn / Katalog / Suche / in CDI

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)

Leukemia, 2021-05, Vol.35 (5), p.1392-1404

2021

Volltextzugriff (PDF)

Recurrent Cytokine Storm in SARS-CoV-2 Infected Patients with Hematolymphoid Malignancy: A New Perspective

South Asian journal of cancer, 2024-04, Vol.13 (2), p.157-162

2024

Volltextzugriff (PDF)

Does Development of Plasmacytosis have a Role in Spontaneous Remission of Acute Myeloid Leukemia?

Indian journal of hematology & blood transfusion, 2021-01, Vol.37 (1), p.167-168

2021

Volltextzugriff (PDF)

PB1949: ROLE OF LAIR1 (CD305) IN FLOW CYTOMETRIC DETECTION OF OCCULT BONE MARROW INVOLVEMENT IN NON‐CLL B‐CELL NON‐HODGKIN LYMPHOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e7801452-n/a

2023

Volltextzugriff (PDF)

Rare Association of Leukocytoclastic Vasculitis in Visceral Leishmaniaisis

Oman medical journal, 2019, Vol.34 (1), p.66-69

2019

Volltextzugriff (PDF)

P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES

HemaSphere, 2023-08, Vol.7 (S3), p.e09323c5-n/a

2023

Volltextzugriff (PDF)

NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies

Blood cancer journal (New York), 2020-05, Vol.10 (5), p.50-50, Article 50

2020

Volltextzugriff (PDF)

P360: MEASURABLE/MINIMAL RESIDUAL DISEASE (MRD) STATUS IS THE MOST RELEVANT INDICATOR OF CLINICAL OUTCOME IN MIXED PHENOTYPIC ACUTE LEUKEMIAS (MPAL)

HemaSphere, 2023-08, Vol.7 (S3), p.e94316c1-n/a

2023

Volltextzugriff (PDF)

Standardization of 13-color high-sensitivity measurable residual disease (MRD) assessment in B-cell lymphoblastic leukemia (B-ALL) treated with novel anti-CD19 immunotherapies

Pediatric hematology oncology journal, 2022, Vol.7 (4), p.S14-S14

2022

Volltextzugriff (PDF)

Expression pattern of CD179 in b-cell acute lymphoblastic leukemia (B-All): A potential utility for lineage assignment and B-ALL MRD monitoring

Pediatric hematology oncology journal, 2022, Vol.7 (4), p.S42-S42

2022

Volltextzugriff (PDF)

Clinical characteristics, laboratory parameters and outcomes of COVID‐19 in cancer and non‐cancer patients from a tertiary Cancer Centre in India

Cancer medicine (Malden, MA), 2021-12, Vol.10 (24), p.8777-8788

2021

Volltextzugriff (PDF)

Granulocytic dysplasia: an indicator of clonal evolution in patients with chronic myeloid leukemia

Blood Research, 2018, 53(2), , pp.180-181

2018

Volltextzugriff (PDF)

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease

Leukemia, 2021-05, Vol.35 (5), p.1392

2021

Volltextzugriff (PDF)

Autosomal dominant familial periodic fever patient with a missense variant c.215G>A (p.Cys72Tyr) in TNFRSF1A gene presenting as neutrophilia

European journal of medical genetics, 2021-05, Vol.64 (5), p.104191, Article 104191

2021

Volltextzugriff (PDF)

Elevated Von Willebrand Factor Antigen Levels are an Independent Risk Factor for Venous Thromboembolism: First Report from North India

Indian journal of hematology & blood transfusion, 2019-07, Vol.35 (3), p.489-495

2019

Volltextzugriff (PDF)

Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation—An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap

Leukemia research, 2022-01, Vol.112, p.106753, Article 106753

2022

Volltextzugriff (PDF)

Detection of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is influenced by the type of transport medium: Implications for diagnosis and monitoring

International journal of clinical practice (Esher), 2021-08, Vol.75 (8), p.e14311-n/a

2021

Volltextzugriff (PDF)

15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic leukemia/lymphoma: Real‐world applicability and challenges

European journal of haematology, 2024-01, Vol.112 (1), p.122-136

2024

Volltextzugriff (PDF)

Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B‐lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease

British journal of haematology, 2022-01, Vol.196 (2), p.374-379

2022

Volltextzugriff (PDF)

Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequencing

Blood, 2020-11, Vol.136 (Supplement 1), p.5-6

2020

Volltextzugriff (PDF)

Acute basophilic leukemia in a patient with down syndrome: A case report and review of literature

International journal of laboratory hematology, 2023-12, Vol.45 (6), p.972-978

2023

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)

Recurrent Cytokine Storm in SARS-CoV-2 Infected Patients with Hematolymphoid Malignancy: A New Perspective

Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkin's Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India

Does Development of Plasmacytosis have a Role in Spontaneous Remission of Acute Myeloid Leukemia?

PB1949: ROLE OF LAIR1 (CD305) IN FLOW CYTOMETRIC DETECTION OF OCCULT BONE MARROW INVOLVEMENT IN NON‐CLL B‐CELL NON‐HODGKIN LYMPHOMA

Rare Association of Leukocytoclastic Vasculitis in Visceral Leishmaniaisis

P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES

NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies

Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant

P360: MEASURABLE/MINIMAL RESIDUAL DISEASE (MRD) STATUS IS THE MOST RELEVANT INDICATOR OF CLINICAL OUTCOME IN MIXED PHENOTYPIC ACUTE LEUKEMIAS (MPAL)

Standardization of 13-color high-sensitivity measurable residual disease (MRD) assessment in B-cell lymphoblastic leukemia (B-ALL) treated with novel anti-CD19 immunotherapies

Expression pattern of CD179 in b-cell acute lymphoblastic leukemia (B-All): A potential utility for lineage assignment and B-ALL MRD monitoring

Clinical characteristics, laboratory parameters and outcomes of COVID‐19 in cancer and non‐cancer patients from a tertiary Cancer Centre in India

Granulocytic dysplasia: an indicator of clonal evolution in patients with chronic myeloid leukemia

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease

Autosomal dominant familial periodic fever patient with a missense variant c.215G>A (p.Cys72Tyr) in TNFRSF1A gene presenting as neutrophilia

Elevated Von Willebrand Factor Antigen Levels are an Independent Risk Factor for Venous Thromboembolism: First Report from North India

Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation—An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap

Detection of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is influenced by the type of transport medium: Implications for diagnosis and monitoring

Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant

Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing

15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic leukemia/lymphoma: Real‐world applicability and challenges

Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B‐lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease

Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequencing

Acute basophilic leukemia in a patient with down syndrome: A case report and review of literature

Suchergebnisse filtern